title: Hypertension - state of the art 2015.
abstract: A conference organised in conjunction with the British Hypertension Society at the Royal College of Physicians (London) assembled an expert panel to present recent advances in the understanding and management of hypertension - the leading reversible risk factor for global morbidity and mortality. Despite recognised therapeutic approaches, less than half of patients on treatment for hypertension achieve blood pressure control to international guideline-based targets. This failure may, in part, be due to uncertainty into optimum treatment strategies, and the PATHWAY studies reporting later this year will hopefully address some outstanding questions relating to the standardised ABCD approach to drug selection. Targeting degradation of natriuretic peptides by LCZ696 (a combination of valsartan and a neutral endopeptidase inhibitor) has demonstrated potential as a novel therapeutic option, with mortality benefits in heart failure beyond that solely attributable to its blood pressure lowering ability. However, critical to any therapeutic strategy is patient involvement, and it is clear that the delivery of patient-centric treatment options is vital to ensure adherence with medication and to facilitate healthier lifestyle decisions.
authors.affiliation: St Bartholomew's Hospital, Barts Health NHS Trust, London, UK cnfloyd@doctors.org.uk.
authors.forename: Christopher N
authors.initials: CN
authors.lastname: Floyd
mesh_terms: D000613:Aminobutyrates; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001713:Biphenyl Compounds; D001794:Blood Pressure; D004338:Drug Combinations; D006801:Humans; D006973:Hypertension / Q000178:diet therapy / Q000188:drug therapy / Q000503:physiopathology; D055118:Medication Adherence; D012982:Sodium, Dietary; D013777:Tetrazoles; D000068756:Valsartan
chemical_list: D000613:Aminobutyrates; D000959:Antihypertensive Agents; D001713:Biphenyl Compounds; D004338:Drug Combinations; D012982:Sodium, Dietary; D013777:Tetrazoles; D000068756:Valsartan; C549068:sacubitril and valsartan sodium hydrate drug combination
keywords: Hypertension; LCZ696; blood pressure; pathway; salt
references.citation: J Hum Hypertens. 2002 Nov;16(11):761-70
references.pmid: 12444537
references.citation: Lancet. 2002 Dec 14;360(9349):1903-13
references.pmid: 12493255
references.citation: J Hum Hypertens. 2003 Feb;17(2):81-6
references.pmid: 12574784
references.citation: JAMA. 2007 Aug 22;298(8):874-9
references.pmid: 17712071
references.citation: Lancet. 2010 Apr 10;375(9722):1255-66
references.pmid: 20236700
references.citation: Lancet. 2014 Apr 5;383(9924):1211-21
references.pmid: 24457205
references.citation: Lancet. 2014 May 31;383(9932):1912-9
references.pmid: 24881995
references.citation: N Engl J Med. 2014 Sep 11;371(11):993-1004
references.pmid: 25176015
references.citation: BMJ. 2015 Mar 18;350:h770
references.pmid: 25788018